Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseasesArticle Published on 2022-11-022022-11-15 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, 치료기술, [키워드] adverse event childhood-onset rheumatic disease Chinese Cohort COVID-19 COVID-19 infection cPass™ cut-off defined disease Disease activity dose Efficacy evaluate female first vaccination humoral immunogenicity immunogenicity increased the risk inhibition median medication Most patient mounted mRNA vaccination mRNA vaccine neutralization Neutralizing antibodies Neutralizing antibody response neutralizing response not affect Paediatric age paediatric rheumatology Patient positive predictor proportion remained response rheumatic disease SARS-CoV-2 SARS-CoV-2 vaccine second vaccination Serious Adverse Event serious complication Seven subgroup analysis symptomatic the SARS-CoV-2 the vaccine two-dose regimen vaccination Vaccine vaccine efficacy vaccine safety were assessed [DOI] 10.1093/rheumatology/keac105 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipientsArticle Published on 2022-10-012022-11-15 Journal: Hepatology communications [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Analysis analyzed Anti-spike anti-Spike IgG Antibody Response AstraZeneca BBIBP-CorV BMI booster response ChAdOx1 Clinical data collected Combination Concentration Control coronavirus correlation different dose dose evaluate evaluated Future groups healthy volunteer Heterologous homologous humoral IgG immunized Immunoglobulin inactivated information liver LTR LTRs Messenger RNA MMF neutralizing antibody nucleocapsid protein Odds ratio positive positive serology Probability prospective cohort study R 2 receiving recipient reduced reduction regimen reported RNA SARS-CoV-2 SARS-CoV-2 anti-spike IgG Serious Adverse Event Side effects significant difference significantly significantly higher Sinopharm Vaccine vaccine dose vaccine platform [DOI] 10.1002/hep4.2034 PMC 바로가기
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19Article Published on 2022-09-172022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, [키워드] 1:1 95% CI assigned booster dose ChAdOx1 ChAdOx1 nCoV-19 COVID-19 COVID-19 vaccine delta variant facilitate first dose geometric mean titer GMT ratio groups healthy Heterologous heterologous prime-boost immunization neutralizing antibody Neutralizing antibody titer non-inferiority trial occurred outcome prime-boost interval Randomized Randomized controlled trial Randomly receive recipient reported Serious Adverse Event subunit subunit vaccines Support T cell response Vaccine Viral vector vaccine wild-type SARS-CoV-2 [DOI] 10.1038/s41467-022-33146-7 PMC 바로가기
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trialArticle Published on 2022-09-122022-11-15 Journal: Nature Communications [Category] SARS, 진단, [키워드] 1:1 age Analysis antibody blinded BNT162b2 booster vaccination cellular immune responses ChAdOx1 nCoV-19 clinical trial COVID-19 COVID-19 vaccination determine dose Endpoint EudraCT Heterologous homologous Immunosuppressed immunosuppressed patients Impaired include mRNA mRNA vaccination mRNA vaccine mRNA-1273 multivariable logistic regression outcome Patient performed Randomized Randomized controlled trial receive reduced SARS-CoV-2 spike SARS-CoV-2-specific T-cell response secondary Serious Adverse Event Seroconversion seroconversion rate seroconvert significantly higher single center Support vaccination Vaccination strategy Vaccine vaccine group [DOI] 10.1038/s41467-022-33036-y PMC 바로가기
Ozone as an adjuvant therapy for COVID-19: A systematic review and meta-analysisResearch article Published on 2022-09-012022-10-05 Journal: International immunopharmacology [Category] 임상, [키워드] 95% CI adjuvant therapy Admission adverse event article benefit C-reactive protein case control study clinical Cochrane Library conducted COVID-19 COVID-19 patients CRP D-dimer D-dimer levels decrease endpoints evaluate Hospital stay ICU ICU admission IL-6 IMPROVE improvement integrative medicine intensive care Laboratory laboratory parameter lactate dehydrogenase LDH management Meta-analysis Mortality objective outcomes Ozone ProQuest random-effects Randomized controlled trial RCTs reduction reported Result safety profile SARS-CoV-2 Serious Adverse Event severe patients Side effect significantly SMD Standard therapy suggested systematic review therapy viral clearance were assessed [DOI] 10.1016/j.intimp.2022.109014 [Article Type] Research article
Efficacy of pharmacological interventions in COVID-19: A network meta-analysisCovid-19의 약리학 적 개입의 효능 : 네트워크 메타 분석Meta-Analysis Published on 2022-09-012022-09-08 Journal: British Journal of Clinical Pharmacology [Category] meta-analysis, 임상, 치료제, [키워드] 95% confidence interval Administered analysed Clinical improvement clinical recovery Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 database Dexamethasone drug Favipiravir followed by head Head-to-head comparison Hydroxychloroquine increase interferon Intervention investigator Lopinavir Lopinavir/ritonavir lower mortality lower risk lower risk of mortality MeSH term moderate to severe Mortality Network meta-analysis Occurrence patients with moderate pharmacological intervention Quantitative analysis Randomized controlled trial reduce reduced Relative risk Remdesivir risk Ritonavir screened Serious Adverse Event Serious Adverse Events severe COVID-19 significantly Standard of care Tocilizumab was performed [DOI] 10.1111/bcp.15338 PMC 바로가기 [Article Type] Meta-Analysis